Trisomy 21 causes skeletal alterations in individuals with Down syndrome (DS), but the causative trisomic gene and a therapeutic approach to rescue these abnormalities are unknown. Individuals with DS display skeletal alterations including reduced bone mineral density, modified bone structure and distinctive facial features. Due to peripheral skeletal anomalies and extended longevity, individuals with DS are increasingly more susceptible to bone fractures. Understanding the genetic and developmental origin of DS skeletal abnormalities would facilitate the development of therapies to rescue these and other deficiencies associated with DS. DYRK1A is found in three copies in individuals with DS and Ts65Dn DS mice and has been hypothesized to be involved in many Trisomy 21 phenotypes including skeletal abnormalities. Return of Dyrk1a copy number to normal levels in Ts65Dn mice rescued the appendicular bone abnormalities, suggesting that appropriate levels of DYRK1A expression are critical for the development and maintenance of the DS appendicular skeleton. Therapy using the DYRK1A inhibitor epigallocatechin-3-gallate improved Ts65Dn skeletal phenotypes. These outcomes suggest that the osteopenic phenotype associated with DS may be rescued postnatally by targeting trisomic Dyrk1a.
Introduction
Individuals with Down syndrome (DS) [OMIM 190685 ; approximately one in 700 live births (1) ] display a multifaceted disorder with over 80 clinically defined phenotypes affecting nearly all organ systems (2) . In addition to cognitive impairment, individuals with DS exhibit alterations in their appendicular skeletons, including an abnormal pattern of skeletal growth in the long bones during adolescence (3) . Both children and adults with DS exhibit a reduction in bone mineral density (BMD) (4) (5) (6) , an abnormal balance of bone formation and resorption during bone remodeling (7) , which likely contribute to the high incidence of osteopenia and osteoporosis present in individuals with DS (8) (9) (10) (11) . Despite a gross structural understanding of the appendicular skeletal phenotypes, little is known about the genetic and cellular bases of altered bone development in individuals with DS.
The Ts(17 16 )65Dn (Ts65Dn) mouse, the most widely used DS model, contains a small marker chromosome that results in three copies of approximately half the gene orthologs found on human chromosome 21 (Hsa 21) (12) . Ts65Dn mice exhibit numerous parallel phenotypes to humans with DS including cognitive, craniofacial, cardiac and bone abnormalities (13) (14) (15) (16) . Ts65Dn mice display a reduction in BMD, as well as osteoporotic-like structural deficiencies in the cortical and trabecular bone in adolescent and adult Ts65Dn skull and femurs (15, 17) . It is hypothesized that deficiencies in osteoblast and osteoclast number and activity likely contribute to the Ts65Dn skeletal phenotype (18) .
Despite the identification of structural bone abnormalities in humans with DS and Ts65Dn mice, little is known regarding how trisomic genes affect bone maintenance and homeostasis. 'Dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A' (DYRK1A) is found in three copies in humans with DS and Ts65Dn mice (19) and is hypothesized to be involved in many DS phenotypes (20) . Analysis of transgenic mice overexpressing Dyrk1a by 1.5-fold (theoretical dosage imbalance associated with trisomic genes in DS) identified severe appendicular skeletal deficiencies and an osteopenic phenotype similar to that observed in Ts65Dn mice (21) . We hypothesize that increased Dyrk1a gene dosage and kinase activity result in the abnormal appendicular skeletal phenotype observed in adolescent Ts65Dn mice.
Parallel methodologies, one genetic and one therapeutic, were used to reduce DYRK1A activity to determine the contribution of Dyrk1a to the Ts65Dn appendicular skeletal phenotype. Ts65Dn mice were bred to Dyrk1a +/− heterozygote mutant mice to normalize the functional Dyrk1a gene copy number to euploid levels on an otherwise trisomic background. Ts65Dn mice were treated with a known DYRK1A inhibitor, epigallocatechin-3-gallate (EGCG), which has been shown to decrease the DYRK1A activity. We hypothesized that both the genetic and therapeutic rescue of DYRK1A activity would improve the abnormal Ts65Dn appendicular skeletal phenotypes.
Results
Dyrk1a gene copy number affects bone density and structure in the Ts65Dn femur
The present data show that the femur in Ts65Dn DS mice exhibits a significantly lower BMD when compared with euploid mice (0.034 ± 0.002 versus 0.043 ± 0.001; P < 0.01), confirming our previous conclusion that trisomy alters the normal mineralization of bone (15) . The return of Dyrk1a to two functional copies in Ts65Dn mice (Ts65Dn, Dyrk1a
) rescued the femoral BMD phenotype to euploid levels (0.041 ± 0.001). Although skull and mandible BMDs were also lowered in Ts65Dn mice, these were not corrected in Ts65Dn, Dyrk1a +/− mice. Loss of one copy of Dyrk1a in euploid mice led to a significant decrease in mandible and skull BMDs and a lowered femur BMD when compared with euploid animals (Supplementary Material, Table S1 ), indicating that the Dyrk1a copy number is important to normal bone growth and maintenance. The microstructure of bone, as measured through microcomputed tomography (µCT) analysis, is also affected in Ts65Dn mice, as we have previously shown (15) . Percent trabecular bone volume (BV) and trabecular thickness, number and separation were rescued to euploid levels in the distal femur of Ts65Dn, Dyrk1a +/− mice ( Fig. 1E-H) . The two-dimensional (2D)
cross-sectional area of the cortical bone was similar between Ts65Dn, Dyrk1a +/− and euploid mice and significantly increased compared with Ts65Dn mice (Fig. 1I) . No significant differences were observed on the 2D cross-sectional perimeter of the bone between Ts65Dn and Ts65Dn, Dyrk1a +/− mice (Fig. 1J ). These data suggest that although the circumference of the periosteal surface in the femur midshaft is unchanged in Ts65Dn, Dyrk1a +/− when compared with Ts65Dn mice, the amount of bone material and the overall thickness of the cortical bone are significantly improved to euploid levels in young adult mice.
Dyrk1a copy number impacts cell number and activity in the Ts65Dn femur Mechanical properties in Ts65Dn, Dyrk1a +/− mice Ts65Dn mouse femurs exhibit a significant decrease in ultimate force (general integrity of the bone), stiffness (related to the mineralization of the bone) and energy to failure (amount of energy required to break the bone) when compared with euploid mice ( Fig. 2A-C) . The force required to break the femur and stiffness were rescued to euploid levels in Ts65Dn, Dyrk1a +/− mice, and energy to failure was increased when compared with Ts65Dn animals ( Fig. 2A-C) . Euploid, Dyrk1a +/− mice exhibit significant reductions in ultimate force and stiffness. The same mice have a lower energy to failure, but this difference was not significant (P = 0.07). Assessment of the material properties of the femur, which take into account the overall size of the bone, revealed that Ts65Dn femurs exhibit a significantly lower toughness (amount of energy required to cause material failure; Fig. 2D ) and normal ultimate stress and modulus (intrinsic strength and stiffness, respectively; Fig. 2E and F) when compared with euploid mice. Toughness is rescued to euploid levels in Ts65Dn, Dyrk1a +/− femurs (Fig. 2D ).
Ts65Dn, Dyrk1a +/− mice exhibit normalized expression of Dyrk1a in the femur Analysis of RNA isolated from the femur of 6-week-old Ts65Dn mice identified a 1.59-fold expression (P = 0.15) of Dyrk1a RNA transcripts when compared with euploid mice. Ts65Dn, Dyrk1a +/− mice exhibited a 1.01-fold Dyrk1a expression in the femur (compared with euploid), and this expression was not different from euploid levels (P = 0.48). The increased copy number of Dyrk1a in the Ts65Dn long bones also translated to DYRK1A kinase activity of 1.33-fold of that found in euploid animals (P = 0.07). Femurs from adolescent Ts65Dn, Dyrk1a +/− mice had 1.25-fold DYRK1A kinase activity when compared with euploid mice (P = 0.13).
Treatment with a DYRK1A inhibitor improves femoral BMD and trabecular microarchitecture in Ts65Dn mice
To determine whether the known DYRK1A inhibitor EGCG (22) could improve the BMD and structural deficits observed in the Ts65Dn skeleton, we treated 3-week-old Ts65Dn and euploid mice with EGCG (∼9 mg/kg/day) or water for 3 weeks. No differences were observed in the weight at 6 weeks of age, the amount of liquid consumed between Ts65Dn control and treated mice or the dosage of EGCG received by Ts65Dn and euploid mice during the treatment period (Supplementary Material, Fig. S1A -C). Ts65Dn mice treated with EGCG (Ts65Dn+EGCG) exhibited a significantly higher femoral BMD when compared with Ts65Dn mice (0.038 ± 0.001 versus 0.034 ± 0.001, P < 0.05), and similar to the genetic rescue, no effects were observed on mandible or skull BMD in Ts65Dn mice treated with postnatal EGCG (Supplementary Material, Table S2 ). Treatment of euploid animals with EGCG did not have any effect on femur, skull or mandible BMD (Supplemental Material, Table S2 ). EGCG treatment showed a positive impact on the Ts65Dn trabecular microarchitecture. Femurs from Ts65Dn+EGCG mice exhibited a significantly higher percent trabecular BV, trabecular number and trabecular thickness when compared with Ts65Dn mice (Fig. 3A , B and D) and were rescued to euploid levels. Additionally, treatment of euploid animals with EGCG did not have a significant impact on trabecular bone microarchitecture when compared with euploid animals (Fig. 3A-D) . Unlike what was observed in trabecular bone, treatment with ∼9 mg/kg/day EGCG for only 3 weeks did not correct the cortical bone phenotype observed in Ts65Dn mice ( Fig. 3E and F) .
EGCG treatment increases mineralization rate in Ts65Dn femurs with limited impact on strength EGCG treatment of Ts65Dn mice led to a significant increase in MAR when compared with Ts65Dn mice, but did not reach Cortical bone analysis revealed a euploid-like 2D cross-sectional area (I) but not perimeter (J) in Ts65Dn, Dyrk1a +/− mice. Data are reported as mean ± SEM. Significance is denoted by brackets between groups (P < 0.05).
Human Molecular Genetics, 2015, Vol. 24, No. 20 | 5689 euploid levels in the cortical bone of the midshaft (Table 2) . Despite significantly increasing MAR, EGCG treatment did not significantly increase overall BFR in the cortical bone of Ts65Dn mice. EGCG treatment had no effect on MS/BS, MAR or BFR in the midshaft of euploid animals. Treatment of Ts65Dn mice with ∼9 mg/kg/day EGCG led to a normalization of BV/TV (Table 2 ). Treatment with EGCG for 3 weeks also increased mineralizing surface (MS/BS), MAR and BFR in the trabecular bone of the distal femur in Ts65Dn mice, but only MAR was returned to euploid levels ( Table 2 ), suggesting that EGCG treatment positively affects osteoblast number and activity in the Ts65Dn distal femur. EGCG treatment also led to a significant decrease in osteoclast number and activity in the trabecular bone of Ts65Dn mice, but these values were not completely rescued to euploid levels at the ∼9 mg/kg/day treatment level. Treatment of euploid mice with EGCG did not affect the mineralization properties or the cellular composition/activity in the distal femur. Ts65Dn mice treated with EGCG exhibited a significant increase in bone toughness when compared with Ts65Dn mice, suggesting that, similar to what was observed in Ts65Dn, Dyrk1a Table S3 ). Other mechanical and material properties of the bone were not improved in Ts65Dn mice with a 3-week, ∼9 mg/kg/day EGCG treatment. EGCG treatment did not significantly affect the mechanical properties of the euploid femur.
DYRK1A activity in the femur after treatment with 9 mg/kg/day EGCG In Ts65Dn mice treated with water, DYRK1A kinase activity was 1.53-fold that of euploid controls (P = 0.24) in protein isolated from 6-week-old femurs. The DYRK1A kinase activity of Ts65Dn mice treated with ∼9 mg/kg/day EGCG was 1.25-fold of euploid levels (P = 0.33).
Discussion
Despite knowing that trisomy of human chromosome 21 causes DS, it is not clear how three copies of more than 300 genes affect the myriad phenotypes associated with the syndrome. Although it was once hypothesized that a single critical chromosomal region influenced all major trisomy 21 phenotypes, mouse models and advanced molecular analysis point to an individual gene or a small group of genes that may be important in a single or multiple DS phenotypes (23, 24) . Other experiments using Human
mouse models of DS have confirmed this recent paradigm shift showing the impact of one or two trisomic genes on specific well-defined DS phenotypes (25) (26) (27) (28) (29) . It has been hypothesized that trisomic DYRK1A contributes to the development of a number of DS phenotypes including cognitive impairment, Alzheimer's disease and skeletal anomalies (20, 30, 31) . Our results indicate that three copies of Dyrk1a are substantially responsible for the postnatal establishment and maintenance of the abnormal adolescent Ts65Dn appendicular bone phenotype. Percent BV, trabecular microarchitecture, bone toughness and distal femur MS, MAR and osteoclast number are all rescued to euploid levels in Ts65Dn, Dyrk1a +/− mice, suggesting that three copies of Dyrk1a are sufficient to cause the abnormal Ts65Dn femoral phenotype. Using the Ts65Dn mouse model, others have shown the importance of DYRK1A in cognitive and neurological phenotypes associated with DS (29) . The association of Dyrk1a with the establishment and maintenance of the abnormal adolescent Ts65Dn appendicular skeleton provides a potential therapeutic target to improve the abnormal bone phenotype in humans with DS. Preclinical trials in mouse models have indicated the efficacy of drug treatment to alleviate some behavioral and cognitive DS phenotypes in mice, but most do not directly treat the product of a trisomic gene (32) . Treatments containing EGCG have been shown to improve some cognitive deficits in trisomic mouse models and in humans with DS, using EGCG doses of ∼100 and 9 mg/kg/day, respectively (30, 33) . Our treatment of Ts65Dn mice for 3 weeks with the same concentration of EGCG used in human studies led to a substantial improvement in the postnatal femoral phenotype at 6 weeks of age. BMD, percent BV and MAR were all significantly improved after EGCG treatment. Critical to the therapeutic potential of EGCG, only limited effects of treatment were observed in the bones of euploid mice. Our parallel genetic and therapeutic data, including a slight reduction in DYRK1A activity in the appendicular skeletal bones, suggest that EGCG treatment affects DYRK1A activity in Ts65Dn mice to alleviate some appendicular skeletal abnormalities.
Further research is necessary to determine the optimal dosage and timing of EGCG treatment of Ts65Dn mice to completely correct the abnormal skeleton. A higher dosage of or extended treatment with EGCG may be necessary to further reduce DYRK1A activity and to correct cortical abnormalities. Yet, euploid, Dyrk1a +/− mice show significantly reduced percent BV, trabecular thickness, 2D cross-sectional perimeter and ultimate force and stiffness when compared with euploid control mice. These phenotypes are similar to those observed in Ts65Dn mice and indicate that both overexpression and inhibition of Dyrk1a may negatively impact bone homeostasis. Transgenic Dyrk1a overexpressing mice display neurological abnormalities as do Dyrk1a +/− mice (34, 35) . Both DYRK1A overexpression and inhibition have been shown to reduce Rest transcript levels that regulate pluripotency and cell fate in DS (36) . Taken together, these studies indicate the importance of an optimal dosage of EGCG that leads to positive phenotypic changes in the abnormal DS skeleton and brain, while avoiding excessive inhibition of DYRK1A activity. We have shown that increased Dyrk1a dosage does not affect the prenatal origin of the abnormal appendicular skeletal phenotype in mouse models of DS (37) , but does affect the postnatal appendicular skeleton. This study has shown that increased Dyrk1a dosage also does not affect Ts65Dn mandibular or skull BMD, although the morphology has similarities to that seen in individuals with DS (14) . Increased expression of other trisomic genes may cause small changes to the prenatal bone structure, and it is still unknown whether increased dosage of Dyrk1a has a primary role in DS craniofacial morphology.
Analysis of the cellular composition and activity in trabecular bone revealed a mechanism that likely explains the osteopenic bone phenotype observed in Ts65Dn mice. MS, a parameter estimating osteoblast number, and MAR/BFR are significantly lower in the distal femur of Ts65Dn mice, suggesting that the bone formation is significantly affected by trisomy. No differences were observed in OS/BS, an alternative measure of osteoblast activity, but this discrepancy is likely because OS/BS is a static measure at a single time point, whereas MS is a dynamic measure assessing the process of bone formation over a 7-day time period. Furthermore, Ts65Dn mice exhibited a significant increase in the number of osteoclasts in the secondary spongiosa of the adolescent distal femur, contrary to what has been previously described in the adult Ts65Dn appendicular skeleton (18) . It is hypothesized that the differences observed between the studies likely result from the analysis of bone at different stages of maturity (6 versus 12 weeks) and suggest that DYRK1A may play a complex role in the regulation of osteoclast number in Ts65Dn mice during skeletal remodeling. Overall, the increased osteoclast number along with the reduction in osteoblast number and activity suggests an inherent deficiency in the maintenance of balance between bone resorption and bone formation in Ts65Dn mice, leading to the osteopenic phenotype observed at 6 weeks of age.
The finding of decreased osteoclast number in the adolescent Ts65Dn distal femur suggests a novel mechanism for the role of Dyrk1a in the postnatal establishment and maintenance of bone. DYRK1A dosage affects cell fate and differentiation in neuronal precursors and embryonic stem cells (36, 38) . It is known that DYRK1A is a negative regulator of the key pro-osteoclastic transcription factor NFATc and thus contrary to what was found, it was hypothesized that increased Dyrk1a expression in the Ts65Dn femur would lead to a decrease in osteoclastogenesis. Analyses of other targets of the multifunctional DYRK1A kinase suggest a number of interactions involving DYRK1A and proteins known to affect osteoclasts (39) . Overexpression of Dyrk1a in the brain of hyperhomocysteinemic mice leads to a significant increase in the phosphorylation of Erk, Mek and Akt (40) . Both pAkt and pErk have been shown to be positive regulators of osteoclastogenesis and bone resorptive activity, suggesting an alternative pathway by which DYRK1A may regulate osteoclasts in the Ts65Dn adolescent skeleton (41) (42) (43) . Alternatively, DYRK1A has been shown to directly phosphorylate cyclic AMP response element binding protein, a known positive regulator of osteoclast differentiation and function (44, 45) .
In addition to osteoclast homeostasis, angiogenesis is a critical component of bone development and growth. Trisomy 21 attenuates angiogenesis through endostatin (a potent anti-angiogenic molecule), and trisomic RCAN1 was found to suppress vascular endothelial growth factor A (46). Anti-angiogenesis or inhibition of VEGF would suppress bone formation, and the enhancement of angiogenesis or activation of VEGF would stimulate bone formation. This suggests that a decrease in bone formation in DS may be caused by the attenuation of angiogenesis. It is still not clear whether angiogenesis may play a role in bone homeostasis in the DS model. However, previous studies demonstrate that EGCG suppresses angiogenesis by inhibiting the activation of HIF-1 and VEGF expression (47) . In our study, the improvement in BV by EGCG likely occurred via mechanisms that are not related to angiogenesis.
Although our results suggest that Dyrk1a is associated with many of the abnormal skeletal phenotypes associated with DS, not all parameters were corrected in Ts65Dn, Dyrk1a +/− mice as differences in the cortical bone perimeter did not reach euploid levels. Dyrk1a RNA levels and DYRK1A kinase activity were not completely reduced to euploid levels in the long bones of Ts65Dn, Dyrk1a +/− mice. These results suggest that RNA expression and DYRK1A activity are variable at a given time point and that other genes found in three copies in Ts65Dn mice having a role in bone maintenance or cortical bone differences could be affecting the appendicular bone phenotype. Treatment with ∼9 mg/kg/day EGCG did not significantly lower the DYRK1A activity level, similar to that found in Ts65Dn, Dyrk1a +/− mice. This measurement was at a static time point and may not have reflected the total decreased DYRK1A activity. It may be that the cumulative changes in the DYRK1A activity over the 3-week treatment period were enough to normalize some bone parameters, and a higher concentration or longer treatment of EGCG will be needed to normalize all bone parameters and DYRK1A activity. Alternatively, a lower EGCG dose may positively affect skeletal phenotypes including those that were not corrected with the present EGCG treatment. EGCG likely affects other proteins and cellular activities beyond those associated with DYRK1A. EGCG has been shown to have antioxidant activities that improve bone precursors (48) as well as an effect on matrix metalloproteinases that decrease osteoclast formation and differentiation in vitro (49) . It is entirely possible that EGCG is affecting these and other mechanisms in the Ts65Dn mouse model to correct appendicular skeletal abnormalities. However, the limited changes in euploid mice given EGCG suggest that EGCG affects Dyrk1a or other trisomic genes in the Ts65Dn mouse model. We have identified increased Dyrk1a gene dosage as a major contributing factor to the abnormal appendicular skeletal phenotype observed in adolescent Ts65Dn mice. Mechanistically, increased osteoclast number and a decrease in the osteoblast number and activity cause a severe imbalance between bone resorption and formation, leading to the osteopenic phenotype observed in Ts65Dn mice. Further research must be conducted to identify the method in which Dyrk1a copy number affects signaling pathways critical to osteoclast and osteoblast differentiation and activity to determine how trisomy for Dyrk1a causes the altered cellular phenotype observed in the Ts65Dn femur. Postnatal treatment of Ts65Dn mice with EGCG, a known inhibitor to DYRK1A, shows promising results as a therapeutic treatment for the abnormal DS bone phenotype. Further research will focus on extending the treatment of Ts65Dn mice with EGCG for longer periods of time, as well as on potentially identifying an additional, but still non-toxic, concentration of EGCG to maximize the positive effects of this therapy on bone development.
Materials and Methods

Animals
Female B6EiC3Sn a/A-Ts(17 16 )65Dn (Ts65Dn) mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). B6C3F 1 mice were bred by crossing B6 females with C3H males. Ts65Dn males were generated at Indiana University-Purdue University Indianapolis (IUPUI) by crossing Ts65Dn females with B6C3F 1 males and identified by polymerase chain reaction (PCR) genotyping (50) . Ts65Dn [approximate 50% B6 and 50% C3H background with small marker (trisomic) chromosome] mothers generated the male mice used for the therapeutic treatment portion of this study. Only male mice were used due to the subfertile nature of Ts65Dn male mice and importance of Ts65Dn female mice in colony maintenance. Trisomic and euploid mice were aged to 3 weeks, at which point they were weaned from their mothers. At the time of weaning, Ts65Dn and euploid mice were randomly assigned either water or 0.124 mg/ml EGCG for liquid consumption ad libitum. The mice were weighed, and solutions were changed every other day for 3 weeks. Measurements of the total liquid volume consumed were taken at the time of changing for the extent of the 3-week period, and the total amount of liquid consumed was calculated over the span of treatment (Supplementary Material, Fig. S1 ). For the reduction of Dyrk1a gene copy number experiment, Dyrk1a heterozygous mutant mice (Dyrk1a +/− ) were obtained from Dr Mariona Arbones (Institut de Recerca Oncologica, Barcelona, Spain). Dyrk1a +/− mice were backcrossed to B6C3F1 mice for seven generations to parallel the genetic background of Ts65Dn mice. Ts65Dn females were then bred to Dyrk1a +/− males to generate the four groups of mice used in the study [euploid, euploid, Dyrk1a +/− (only one functional copy of Dyrk1a), Ts65Dn and Ts65Dn, Dyrk1a +/− (two functional copies of Dyrk1a)]. Mice were Ts65Dn genotyped as described earlier, and Dyrk1a mice were genotyped as described previously (51) . Male mice were weaned at 3 weeks of age and allowed to age to 6 weeks. For both study groups, mice were injected intraperitoneally at 5 weeks of age with 0.2 ml of 0.6% Calcein green dye diluted in saline solution, as well as 4 days later with 0.2 ml of 1.0% Alizarin red dye. Three days after the Alizarin red injection, mice were euthanized and weighed. The femur, mandible and skull were subsequently extracted and placed in 70% ethanol and stored at −20°C until further use. All animal use and protocols were approved by the IACUC Committee at IUPUI School of Science and adhere to the requirements in the NIH Guide for the Care and Use of Laboratory Animals.
Protein isolation, immunoprecipitation and Dyrk1a kinase assay
Six-week-old mice were euthanized and femurs were extracted for protein [euploid (n = 6), Ts65Dn (n = 6), Ts65Dn, Dyrk1a +/− (n = 3); and euploid + water (n = 5), Ts65Dn + water (n = 6), Ts65Dn + EGCG (n = 3)]. The distal and proximal femurs were removed and the marrow cavity flushed with 1× phosphate-buffered saline (PBS) prior to being snap frozen in liquid nitrogen. Bones were ground into a powder in a mortar and pestle with liquid nitrogen and placed into RIPA buffer with 1× protease cocktail inhibitor (Roche, Indianapolis, IN, USA). Samples were then homogenized using a portable rotary grinder, incubated at 4°C and centrifuged at 10 000 rpm for 10 min. Protein concentration was analyzed using a Bradford assay. A total of 300 μg protein was cleared of extraneous antibodies, incubated with mouse anti-DYRK1A antibody (7D10, Abnova, Taipei, Taiwan) and immobilized with protein-G Sepharose beads overnight. The beads were washed and subjected to a protein kinase assay, as described previously (33, 52 2 µ harmine (a strong inhibitor of DYRK1A activity) was added to some samples and used as a control to ensure proper detection of DYRK1A activity. Samples were incubated for 50 min at 30°C, and the reaction was stopped with 1/3 vol. 100 m EDTA. An aliquot of 10 µl of each sample was blotted onto P81 paper (samples performed in triplicate) and washed extensively with 5% phosphoric acid. Counts were made in a Beckman Liquid Scintillation counter. Relative kinase activity was determined by subtracting background activity from untreated and EGCG-treated euploid and trisomic samples. Comparisons were made using euploid values as the standard. 
RNA isolation and qPCR
RNA was isolated from the 6-week-old femur of euploid, Ts65Dn and Ts65Dn, Dyrk1a +/− animals (n = 3 in each group) using the Trizol/chloroform method and cleared of extraneous DNA using DNAase as described in the RNA micro kit purchased from Invitrogen (Grand Island, NY, USA). Briefly, femurs were extracted from mice, proximal and distal ends were removed and the marrow cavity was flushed with 1× PBS. Femurs were snap frozen in liquid nitrogen and kept at −80°C until processing. Femurs were ground in liquid nitrogen using a sterile mortar and pestle, placed in Trizol and further homogenized using a tissue rotary homogenizer. Chloroform was added to each sample to induce phase separation, and RNA was eluted from the aqueous phase using isopropanol. A total of 500 ng RNA was converted to cDNA using Taqman reverse transcription reagents, and quantitative PCR (qPCR) was performed using 
Dual energy X-ray absorptiometry
The bone mineral content (BMC) of the femur was analyzed using the Lunar Piximus DEXA machine (PIXImus Lunar Corp., Madison, WI, USA). The machine was calibrated prior to each use. The femurs were placed caudal side down on the densitometer with ultrahigh resolution (0.18 × 0.18 mm 2 ) (54). Lunar Piximus 2 2.0 software was used to assess BMD, BMC and total bone area measurements.
µCT imaging and analysis
Femurs were imaged using the Skyscan 1172 µCT machine at the Indiana University School of Medicine and analyzed using the CTrecon and CTan software from Skyscan, as described previously (15) . Briefly, femurs were thawed and placed in a Styrofoam mold fitted to the rotating stage in the machine. Bones were scanned, and the collection of images was reconstructed for analysis. Three-dimensional and 2D analyses were conducted on the trabecular and cortical bones, respectively, to obtain the parameters addressed in the study.
Tissue processing and histomorphometry
The left femur was separated at the midshaft, and the proximal and distal femurs were processed, cut and sectioned as described previously (15) . One section per femur midshaft was read using a D-FL Epi-Fluorescence attachment on a Nikon Eclipse 80i DIC microscope. MS was assessed by measuring the double-label perimeter (dl.P), single-label perimeter (sl.P) and total perimeter using BioQuant software (R&M Biometrics, Nashville, TN, USA) [MS = (dl. P. + 1/2 sl.P)/total perimeter]. MAR was determined by measuring the distance between the two fluorochrome labels, using ImageJ (National Institutes of Health, Bethesda, MD, USA), and averaging the distance by the days between label applications (4). MS and MAR were used to calculate BFR (BFR = MS × MAR × 365 days/ year). These measures were made at the periosteal surface of the femur midshaft. For dynamic analysis of the distal femur, trabecular bone was thin sectioned (4 μm) using a rotary microtome with a tungsten-carbide knife. Dynamic analysis was carried out using Bioquant software as mentioned earlier. For static histomorphometry of trabecular bone, 4 μm thin sections were deplasticized in acetone and stained for either osteoid using a modification of the Von Kossa-MacNeal's tetrachrome protocol (55) or osteoclasts using a tartrate-resistant acid phosphatase (TRAP) stain (56) . OS/ BS was quantified using Bioquant. For TRAP staining, OcS to BS and osteoclast number per 1 mm tissue were quantified using Bioquant image analysis software.
Mechanical testing
The mechanical strength of the femur was determined by threepoint bending (57) using a miniature materials machine at the Indiana University School of Medicine, as described previously (15) . Briefly, femurs were thawed, placed posterior side down on the three-point bending apparatus with lower supports fixed at a distance of 7 mm apart and positioned in a manner so that the force would be applied to the midpoint of the bone. The femur was preloaded using 0.1 N to establish contact with the bone. The displacement rate was set at 0.1 mm/s. Once preloaded, force was applied until the bone was broken. Data were gathered by the system and Microsoft Excel was used to determine the ultimate load, energy to failure and stiffness of the bone. Material properties were calculated as described previously (15) .
Statistical analysis
Data were analyzed in Microsoft Excel by comparing individual groups using a standard two-tailed t-test and significance was denoted by P ≤ 0.05.
Supplementary Material
Supplementary Material is available at HMG online.
